Cyclodextrins, Blood-Brain Barrier, and Treatment of Neurological Diseases

M. Vecsernyés, Ferenc Fenyvesi, I. Bácskay, M. Deli, Lajos Szente, Éva Fenyvesi

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Biological barriers are the main defense systems of the homeostasis of the organism and protected organs. The blood-brain barrier (BBB), formed by the endothelial cells of brain capillaries, not only provides nutrients and protection to the central nervous system but also restricts the entry of drugs, emphasizing its importance in the treatment of neurological diseases. Cyclodextrins are increasingly used in human pharmacotherapy. Due to their favorable profile to form hydrophilic inclusion complexes with poorly soluble active pharmaceutical ingredients, they are present as excipients in many marketed drugs. Application of cyclodextrins is widespread in formulations for oral, parenteral, nasal, pulmonary, and skin delivery of drugs. Experimental and clinical data suggest that cyclodextrins can be used not only as excipients for centrally acting marketed drugs like antiepileptics, but also as active pharmaceutical ingredients to treat neurological diseases. Hydroxypropyl-β-cyclodextrin received orphan drug designation for the treatment of Niemann-Pick type C disease. In addition to this rare lysosomal storage disease with neurological symptoms, experimental research revealed the potential therapeutic use of cyclodextrins and cyclodextrin nanoparticles in neurodegenerative diseases, stroke, neuroinfections and brain tumors. In this context, the biological effects of cyclodextrins, their interaction with plasma membranes and extraction of different lipids are highly relevant at the level of the BBB.

Original languageEnglish
Pages (from-to)711-729
Number of pages19
JournalArchives of Medical Research
Volume45
Issue number8
DOIs
Publication statusPublished - Nov 1 2014

Fingerprint

Cyclodextrins
Blood-Brain Barrier
Pharmaceutical Preparations
Excipients
Therapeutics
Type C Niemann-Pick Disease
Orphan Drug Production
Lysosomal Storage Diseases
Therapeutic Uses
Nose
Brain Neoplasms
Neurodegenerative Diseases
Anticonvulsants
Nanoparticles
Homeostasis
Central Nervous System
Endothelial Cells
Stroke
Cell Membrane
Lipids

Keywords

  • Blood-brain barrier
  • CNS diseases
  • Cyclodextrins
  • Drug delivery
  • Tight junctions

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Cyclodextrins, Blood-Brain Barrier, and Treatment of Neurological Diseases. / Vecsernyés, M.; Fenyvesi, Ferenc; Bácskay, I.; Deli, M.; Szente, Lajos; Fenyvesi, Éva.

In: Archives of Medical Research, Vol. 45, No. 8, 01.11.2014, p. 711-729.

Research output: Contribution to journalArticle

Vecsernyés, M. ; Fenyvesi, Ferenc ; Bácskay, I. ; Deli, M. ; Szente, Lajos ; Fenyvesi, Éva. / Cyclodextrins, Blood-Brain Barrier, and Treatment of Neurological Diseases. In: Archives of Medical Research. 2014 ; Vol. 45, No. 8. pp. 711-729.
@article{29475f20571142ad855cdcc19348a58c,
title = "Cyclodextrins, Blood-Brain Barrier, and Treatment of Neurological Diseases",
abstract = "Biological barriers are the main defense systems of the homeostasis of the organism and protected organs. The blood-brain barrier (BBB), formed by the endothelial cells of brain capillaries, not only provides nutrients and protection to the central nervous system but also restricts the entry of drugs, emphasizing its importance in the treatment of neurological diseases. Cyclodextrins are increasingly used in human pharmacotherapy. Due to their favorable profile to form hydrophilic inclusion complexes with poorly soluble active pharmaceutical ingredients, they are present as excipients in many marketed drugs. Application of cyclodextrins is widespread in formulations for oral, parenteral, nasal, pulmonary, and skin delivery of drugs. Experimental and clinical data suggest that cyclodextrins can be used not only as excipients for centrally acting marketed drugs like antiepileptics, but also as active pharmaceutical ingredients to treat neurological diseases. Hydroxypropyl-β-cyclodextrin received orphan drug designation for the treatment of Niemann-Pick type C disease. In addition to this rare lysosomal storage disease with neurological symptoms, experimental research revealed the potential therapeutic use of cyclodextrins and cyclodextrin nanoparticles in neurodegenerative diseases, stroke, neuroinfections and brain tumors. In this context, the biological effects of cyclodextrins, their interaction with plasma membranes and extraction of different lipids are highly relevant at the level of the BBB.",
keywords = "Blood-brain barrier, CNS diseases, Cyclodextrins, Drug delivery, Tight junctions",
author = "M. Vecserny{\'e}s and Ferenc Fenyvesi and I. B{\'a}cskay and M. Deli and Lajos Szente and {\'E}va Fenyvesi",
year = "2014",
month = "11",
day = "1",
doi = "10.1016/j.arcmed.2014.11.020",
language = "English",
volume = "45",
pages = "711--729",
journal = "Archives of Medical Research",
issn = "0188-4409",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Cyclodextrins, Blood-Brain Barrier, and Treatment of Neurological Diseases

AU - Vecsernyés, M.

AU - Fenyvesi, Ferenc

AU - Bácskay, I.

AU - Deli, M.

AU - Szente, Lajos

AU - Fenyvesi, Éva

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Biological barriers are the main defense systems of the homeostasis of the organism and protected organs. The blood-brain barrier (BBB), formed by the endothelial cells of brain capillaries, not only provides nutrients and protection to the central nervous system but also restricts the entry of drugs, emphasizing its importance in the treatment of neurological diseases. Cyclodextrins are increasingly used in human pharmacotherapy. Due to their favorable profile to form hydrophilic inclusion complexes with poorly soluble active pharmaceutical ingredients, they are present as excipients in many marketed drugs. Application of cyclodextrins is widespread in formulations for oral, parenteral, nasal, pulmonary, and skin delivery of drugs. Experimental and clinical data suggest that cyclodextrins can be used not only as excipients for centrally acting marketed drugs like antiepileptics, but also as active pharmaceutical ingredients to treat neurological diseases. Hydroxypropyl-β-cyclodextrin received orphan drug designation for the treatment of Niemann-Pick type C disease. In addition to this rare lysosomal storage disease with neurological symptoms, experimental research revealed the potential therapeutic use of cyclodextrins and cyclodextrin nanoparticles in neurodegenerative diseases, stroke, neuroinfections and brain tumors. In this context, the biological effects of cyclodextrins, their interaction with plasma membranes and extraction of different lipids are highly relevant at the level of the BBB.

AB - Biological barriers are the main defense systems of the homeostasis of the organism and protected organs. The blood-brain barrier (BBB), formed by the endothelial cells of brain capillaries, not only provides nutrients and protection to the central nervous system but also restricts the entry of drugs, emphasizing its importance in the treatment of neurological diseases. Cyclodextrins are increasingly used in human pharmacotherapy. Due to their favorable profile to form hydrophilic inclusion complexes with poorly soluble active pharmaceutical ingredients, they are present as excipients in many marketed drugs. Application of cyclodextrins is widespread in formulations for oral, parenteral, nasal, pulmonary, and skin delivery of drugs. Experimental and clinical data suggest that cyclodextrins can be used not only as excipients for centrally acting marketed drugs like antiepileptics, but also as active pharmaceutical ingredients to treat neurological diseases. Hydroxypropyl-β-cyclodextrin received orphan drug designation for the treatment of Niemann-Pick type C disease. In addition to this rare lysosomal storage disease with neurological symptoms, experimental research revealed the potential therapeutic use of cyclodextrins and cyclodextrin nanoparticles in neurodegenerative diseases, stroke, neuroinfections and brain tumors. In this context, the biological effects of cyclodextrins, their interaction with plasma membranes and extraction of different lipids are highly relevant at the level of the BBB.

KW - Blood-brain barrier

KW - CNS diseases

KW - Cyclodextrins

KW - Drug delivery

KW - Tight junctions

UR - http://www.scopus.com/inward/record.url?scp=84924765346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924765346&partnerID=8YFLogxK

U2 - 10.1016/j.arcmed.2014.11.020

DO - 10.1016/j.arcmed.2014.11.020

M3 - Article

VL - 45

SP - 711

EP - 729

JO - Archives of Medical Research

JF - Archives of Medical Research

SN - 0188-4409

IS - 8

ER -